Three Are Thwarted In Latest Lacosamide Gambit In US
Three generics firms have failed in their latest attempt to invalidate a patent protecting UCB’s lacosamide-based Vimpat epilepsy brand until 2022.
Three generics firms have failed in their latest attempt to invalidate a patent protecting UCB’s lacosamide-based Vimpat epilepsy brand until 2022.